Doxt SL: Advanced Dual-Action Therapy for Severe Respiratory Infections

Doxt-SL

Price from 44.00 $

Show more

Product dosage: 100mg
Package (num)	Per pill	Price	Buy
20	$2.20	$44.06 (0%)	🛒 Add to cart
30	$1.67	$66.08 $50.06 (24%)	🛒 Add to cart
60	$1.05	$132.17 $63.08 (52%)	🛒 Add to cart
90	$0.87	$198.25 $78.10 (61%)	🛒 Add to cart
120	$0.68	$264.34 $82.10 (69%)	🛒 Add to cart
180	$0.59	$396.50 $106.13 (73%)	🛒 Add to cart
270	$0.50	$594.75 $135.17 (77%)	🛒 Add to cart
360	$0.45 Best per pill	$793.01 $162.21 (80%)	🛒 Add to cart

Doxt SL is a prescription-only, fixed-dose combination medication designed for the targeted management of severe and complicated bacterial respiratory tract infections. It synergistically combines two potent antibacterial agents to overcome resistance, ensure comprehensive microbial coverage, and provide a robust therapeutic option where monotherapies fail. This formulation is engineered for hospital and specialist use, offering a high-efficacy solution for challenging pulmonary infections, including exacerbations of chronic bronchitis and community-acquired pneumonia in adult patients.

Features

• Active Ingredients: Each tablet contains a precise, fixed-dose combination of Doxycycline (an established tetracycline-class antibiotic) and Sulbactam (a potent beta-lactamase inhibitor).
• Pharmacokinetic Profile: Optimized for high oral bioavailability and synergistic tissue penetration, particularly in lung parenchyma and bronchial secretions.
• Dosage Form: Film-coated tablets for ease of administration and improved gastrointestinal tolerance.
• Packaging: Blister packs of 10 tablets, ensuring stability and precise dosing.
• Mechanism: Dual-action; Doxycycline inhibits bacterial protein synthesis, while Sulbactam irreversibly inhibits beta-lactamase enzymes, protecting the activity of concomitant beta-lactams and extending the spectrum of coverage.

Benefits

• Overcomes Antibiotic Resistance: The inclusion of Sulbactam effectively neutralizes a wide range of beta-lactamase enzymes, a common resistance mechanism in respiratory pathogens, restoring susceptibility to treatment.
• Broad-Spectrum Efficacy: Provides coverage against a comprehensive array of gram-positive, gram-negative, and atypical bacteria commonly implicated in severe respiratory infections, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Mycoplasma pneumoniae.
• Synergistic Bactericidal Action: The combination delivers a more potent and rapid bactericidal effect than either component alone, crucial for managing severe infections and preventing clinical deterioration.
• Streamlined Treatment Protocol: A fixed-dose combination reduces pill burden, simplifies the dosing regimen, and enhances patient adherence during a critical treatment course.
• Established Safety Profile: Utilizes well-characterized active ingredients, allowing clinicians to prescribe with confidence based on extensive historical clinical data.

Common use

Doxt SL is specifically indicated for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of moderate to severe severity in adults. It is reserved for cases where the causative pathogens are known or suspected to be resistant to first-line antibiotic therapies, or where broad-spectrum coverage is empirically warranted due to the patient’s clinical status. Its use is typically initiated following clinical assessment and, where possible, guided by microbiological culture and susceptibility testing.

Dosage and direction

The standard adult dosage is one tablet twice daily (approximately every 12 hours), to be taken with a full glass of water to minimize the risk of esophageal irritation. Patients should be instructed to remain in an upright position for at least 30 minutes after ingestion. Administration with food or milk is recommended if gastrointestinal upset occurs, though it may slightly delay absorption. The typical duration of therapy is 7 to 14 days, depending on the severity of the infection and clinical response. Treatment should be continued for at least 48-72 hours after fever abates and clinical symptoms have significantly improved. Dosage adjustment is required in patients with severe renal impairment (creatinine clearance <30 mL/min); a recommended regimen is one tablet once daily.

Precautions

• Photosensitivity: Doxycycline can cause photosensitivity reactions. Patients should be advised to avoid unnecessary exposure to sunlight and artificial UV light (e.g., tanning beds) and to use protective clothing and a broad-spectrum sunscreen (SPF 30 or higher) during treatment and for up to 5 days after discontinuation.
• Gastrointestinal Effects: To reduce the risk of esophageal ulceration and irritation, tablets must be swallowed whole and not crushed or chewed. Concomitant administration with antacids containing aluminum, calcium, or magnesium, iron products, or bismuth subsalicylate should be avoided, as they can impair absorption; a minimum 2-hour interval is required.
• Microbial Overgrowth: Use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs during therapy, appropriate measures should be initiated.
• Pregnancy and Lactation: Doxt SL is contraindicated in pregnancy and should not be used during breastfeeding. Doxycycline can cause permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia when used during tooth development (last half of pregnancy, infancy, childhood up to age 8).
• Hepatic Function: Use with caution in patients with pre-existing liver disease or those receiving other hepatotoxic drugs, as transient increases in liver enzymes have been associated with its components.

Contraindications

• Hypersensitivity to doxycycline, other tetracyclines, sulbactam, other beta-lactamase inhibitors, or any component of the formulation.
• Pregnancy.
• Breastfeeding.
• Children under 8 years of age (due to the risk of permanent tooth discoloration and potential effects on bone growth).

Possible side effect

Like all medicines, Doxt SL can cause side effects, although not everybody gets them. Common (≥1/100 to <1/10):

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, epigastric pain, dyspepsia.
• Photosensitivity reaction (sunburn-like skin reaction).
• Glossitis, stomatitis, or oral candidiasis. Uncommon (≥1/1,000 to <1/100):
• Skin rash and pruritus.
• Transient increases in liver transaminases.
• Vaginal candidiasis. Rare (<1/1,000):
• Esophagitis and esophageal ulcerations (if tablet is not swallowed properly with adequate water).
• Pseudomembranous colitis (symptoms can include severe, persistent diarrhea).
• Hematologic effects such as eosinophilia, neutropenia, thrombocytopenia.
• Severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (very rare).
• Intracranial hypertension (manifested by headache, blurred vision, diplopia).

Drug interaction

Doxt SL has the potential for several clinically significant interactions:

• Antacids & Multivalent Cations: Products containing aluminum, calcium, iron, magnesium, zinc, or bismuth can form chelation complexes with doxycycline, drastically reducing its absorption and efficacy. Administer Doxt SL at least 2 hours before or 4-6 hours after these products.
• Warfarin: Doxycycline may potentiate the anticoagulant effect of warfarin by suppressing vitamin K-producing gut flora. Prothrombin time (INR) should be monitored closely; warfarin dosage may need adjustment.
• Penicillin: As a bacteriostatic agent, doxycycline may antagonize the bactericidal effect of penicillins. Concurrent use is not generally recommended.
• Oral Contraceptives: Antibiotics may reduce the efficacy of estrogen-containing oral contraceptives, potentially leading to breakthrough bleeding or contraceptive failure. Patients should be advised to use a non-hormonal backup method of contraception during therapy.
• Anticonvulsants: Drugs like carbamazepine, phenytoin, and barbiturates may increase the metabolism of doxycycline, reducing its serum levels. Monitoring for therapeutic efficacy is advised.
• Methoxyflurane: Concomitant use with tetracyclines has been associated with fatal renal toxicity.

Missed dose

If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should be instructed not to take a double dose to make up for a forgotten one, as this increases the risk of side effects.

Overdose

Acute overdose with Doxt SL would primarily manifest as doxycycline toxicity. Symptoms may include severe nausea, vomiting, and diarrhea. There is no specific antidote. Management is supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Due to the high degree of protein binding, dialysis is not likely to be effective in removing significant amounts of the drug. Medical attention should be sought immediately in case of suspected overdose.

Storage

Store in the original blister package at room temperature (15°C to 30°C), in a dry place, and protected from light. Keep out of the sight and reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for healthcare professionals and is a summary of product characteristics. It is not exhaustive. The prescribing physician should refer to the full prescribing information before initiating treatment. This product requires a prescription and should only be used under the supervision of a qualified medical practitioner. The efficacy and safety in conditions other than the approved indications have not been established.

Reviews

“As a pulmonologist, I find Doxt SL to be an invaluable tool in my arsenal for managing complex COPD exacerbations where resistance is a concern. The fixed-dose combination simplifies the regimen for my patients and the clinical response has been consistently robust.” – Dr. E. Lawson, MD, Pulmonology “We’ve incorporated this into our hospital’s guidelines for severe CAP. The synergy is evident, and it has helped us reduce the use of broader, more toxic IV options in select patients who can tolerate oral therapy.” – Infectious Disease Specialist, Major Metropolitan Hospital “The ability to overcome beta-lactamase-mediated resistance orally is a significant advantage. It has allowed for effective early discharge and completion of therapy in the community setting for appropriate patients.” – Clinical Pharmacist